MetaCap

Akebia Therapeutics (AKBA) vs Genelux (GNLX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Genelux (GNLX) has outperformed Akebia Therapeutics (AKBA) over the past year, losing 56.3% versus a loss of 75.1%. Akebia Therapeutics is the larger company by market cap ($107.0 million vs $103.4 million), about 1.0 times the size. Akebia Therapeutics converts more of its revenue into profit, with a net margin of -2.3% versus -401812.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AKBA-75.13%GNLX-56.25%
+17%-31%-80%
Nov 21, 20251 yearNov 20, 2026
AKBA-42.46%GNLX-63.89%
+521%+211%-99%
Jan 23, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AKBA versus GNLX key metrics
MetricAKBAGNLX
Share price$0.3855$2.17
Market cap$107.04M$103.36M
1-day change-8.71%-4.82%
YTD return-76.06%-50.23%
1-year return-75.13%-56.25%
5-year return-85.56%—
EPS (TTM)$-0.17$-0.88
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$236.20M$8.00K
Revenue growth (YoY)+47.46%0.00%
Net income (latest FY)$-5.34M$-32.15M
Gross margin83.29%—
Operating margin9.95%-415175.00%
Net margin-2.26%-401812.50%
52-week high$1.73$5.89
52-week low$0.361$1.77
Distance from 52-week high-77.72%-63.16%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+678.21%+767.74%
Average volume8.05M333.31K
Shares outstanding277.66M47.63M
Employees19425
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GNLX has outperformed AKBA by 18.9 percentage points over the past year.
  • Akebia Therapeutics is more profitable, keeping -2.3 cents of every revenue dollar as net income versus -401812.5 cents for Genelux.
  • Akebia Therapeutics grew revenue faster in its latest fiscal year (+47.46% vs 0.00%).

About Akebia Therapeutics

AKBA stock →

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.

Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees

About Genelux

GNLX stock →

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

AKBA vs GNLX FAQ

Which is bigger, Akebia Therapeutics or Genelux?

Akebia Therapeutics (AKBA) is larger, with a market capitalization of $107.04M compared with $103.36M for Genelux (GNLX).

Which stock has performed better over the past year, AKBA or GNLX?

GNLX returned -56.25% over the past 12 months, compared with -75.13% for AKBA (price return, excluding dividends). Past performance does not predict future results.

Are Akebia Therapeutics and Genelux in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons